Download video

Treatment Goals for Lower Risk MDS

290 views

OncLive

8 years ago

Treatment Goals for Lower Risk MDS

Treatment Goals for Lower Risk MDS

Treatment Goals for Lower Risk MDS
7:46
Treatment Goals for Lower Risk MDS
by OncLive
Treatment Goals for Higher Risk MDS
7:26
Treatment Goals for Higher Risk MDS
by OncLive
How is lower-risk MDS treated?
2:21
How is lower-risk MDS treated?
by You and MDS
Improving the treatment of low-risk MDS: luspatercept, treatment sequencing \& disease classification
2:12
Improving the treatment of low-risk MDS: luspatercept, treatment sequencing \& disease classification
by VJHemOnc – Video Journal of Hematology \& HemOnc
Novel Treatment Strategies in Low-Risk MDS: Challenges and Emerging Therapies
18:14
Novel Treatment Strategies in Low-Risk MDS: Challenges and Emerging Therapies
by HMP Education
Realigning MDS treatment goals
1:57
Realigning MDS treatment goals
by VJHemOnc – Video Journal of Hematology \& HemOnc
The main treatment goals in LR-MDS and how these differ from HR-MDS
1:13
The main treatment goals in LR-MDS and how these differ from HR-MDS
by VJHemOnc – Video Journal of Hematology \& HemOnc
A Unified Approach to Lower Risk MDS: Standard and Emerging Therapies
21:55
A Unified Approach to Lower Risk MDS: Standard and Emerging Therapies
by HMP Education
Managing and Treating MDS
4:48
Managing and Treating MDS
by You and MDS
MDS: treating high and low-risk disease
3:15
MDS: treating high and low-risk disease
by VJHemOnc – Video Journal of Hematology \& HemOnc
The promise of luspatercept for the treatment of lower-risk MDS
0:56
The promise of luspatercept for the treatment of lower-risk MDS
by VJHemOnc – Video Journal of Hematology \& HemOnc
Key highlights in MDS: treating lower-risk \& higher-risk disease, trial updates, and more
13:39
Key highlights in MDS: treating lower-risk \& higher-risk disease, trial updates, and more
by VJHemOnc – Video Journal of Hematology \& HemOnc
Novel Treatment Strategies in Low-Risk MDS: Case Study
18:42
Novel Treatment Strategies in Low-Risk MDS: Case Study
by HMP Education
Lower-risk MDS in 2021: luspatercept, imetelstat \& roxadustat
4:35
Lower-risk MDS in 2021: luspatercept, imetelstat \& roxadustat
by VJHemOnc – Video Journal of Hematology \& HemOnc
Treatment algorithm for low-risk MDS
11:33
Treatment algorithm for low-risk MDS
by VJHemOnc – Video Journal of Hematology \& HemOnc
High Risk MDS Treatment Strategies
1:32:06
High Risk MDS Treatment Strategies
by AAMDSIF
The optimal treatment of lower risk MDS
11:53
The optimal treatment of lower risk MDS
by VJHemOnc – Video Journal of Hematology \& HemOnc
How Do Clinicians Communicate With Patients About Low-Risk MDS?
2:28
How Do Clinicians Communicate With Patients About Low-Risk MDS?
by Blood Cancers Today
A new set of treatment options for low-risk MDS
3:38
A new set of treatment options for low-risk MDS
by VJHemOnc – Video Journal of Hematology \& HemOnc
The current standard of care for patients with lower-risk MDS
1:20
The current standard of care for patients with lower-risk MDS
by VJHemOnc – Video Journal of Hematology \& HemOnc